Tejas Savant
Stock Analyst at Morgan Stanley
(2.40)
# 2,495
Out of 5,113 analysts
250
Total ratings
44.68%
Success rate
-0.55%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $42.92 | +11.84% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $567.83 | +17.99% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $64.46 | +31.86% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $20.53 | +16.90% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $8.55 | +28.65% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $231.96 | +14.24% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $220.69 | +20.08% | 12 | Dec 2, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $85 → $110 | $91.09 | +20.76% | 3 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $16.05 | +24.61% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $74.95 | +1.40% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $17.00 | -5.88% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $134.78 | -22.10% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $11.27 | +6.48% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $11.83 | -32.38% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.95 | +41.41% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $9.42 | -25.65% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.43 | +45.77% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $6.55 | +220.61% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.84 | +8.70% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.10 | +393.83% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $1.94 | +209.28% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.61 | +116.92% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.15 | -12.70% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.79 | +458.66% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $99.74 | -26.81% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $197.06 | +26.86% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $6.69 | +1,394.77% | 5 | May 12, 2022 |
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $42.92
Upside: +11.84%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $567.83
Upside: +17.99%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $64.46
Upside: +31.86%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $20.53
Upside: +16.90%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $8.55
Upside: +28.65%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $231.96
Upside: +14.24%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $220.69
Upside: +20.08%
GRAIL
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $85 → $110
Current: $91.09
Upside: +20.76%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $16.05
Upside: +24.61%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $74.95
Upside: +1.40%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $17.00
Upside: -5.88%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $134.78
Upside: -22.10%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $11.27
Upside: +6.48%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $11.83
Upside: -32.38%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.95
Upside: +41.41%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $9.42
Upside: -25.65%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.43
Upside: +45.77%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $6.55
Upside: +220.61%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.84
Upside: +8.70%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.10
Upside: +393.83%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $1.94
Upside: +209.28%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.61
Upside: +116.92%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.15
Upside: -12.70%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.79
Upside: +458.66%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $99.74
Upside: -26.81%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $197.06
Upside: +26.86%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $6.69
Upside: +1,394.77%